Your trusted source for investing success

Tag: immuno-oncology

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343

Pieris Pharmaceuticals (NASDAQ:PIRS) has announced that the first patient has been does in its Phase 1 clinical trial of PRS-343, its lead proprietary immuno-oncology drug candidate.

As quoted in the press release:
PRS-343 is a first-in-class bispecific antibody-Anticalin fusion protein and functions as a tumor-targeted immune costimulatory 4-1BB agonist. The trial, a

5 Top Biotech Stocks on the TSX Year-to-date

5 Top Biotech Stocks on the TSX Year-to-date

The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.

Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
5 Top NASDAQ Biotech Stocks: Infinity Pharmaceuticals Gains 84 Percent